Actis Biologics Inc., a US-based pharmaceutical company, has received worldwide license for Angiozyme from Sirna and Chiron, who co-developed this novel compound with Actis. Angiozyme, a ribozyme based anti-cancer agent, has demonstrated activity against colon cancer in phase II clinical trials.
Someone is stealing equipment from a local hospital that is used to detect colon cancer.
Actis Biologics Inc., a US-based pharmaceutical company, has received worldwide license for Angiozyme from Sirna and Chiron, who co-developed this novel compound with Actis. Angiozyme, a ribozyme based anti-cancer agent, has demonstrated activity against colon cancer in phase II clinical trials.
Despite the benefits of walking -- including a lower risk of heart disease, diabetes, high blood pressure, and colon cancer -- only 15 percent of American children walk to school, the U.S. Centers for Disease Control and Prevention has concluded from new research.
The first drug that promises to attack cancer by choking off its blood supply began shipping hours after being approved by the FDA. The treatment for advanced colon cancer called Avastin, will cost each patient about $4,400 per month.
Contact:
Copyright © 2005 Colon Cancer Solutions.com All Rights Reserved